Last updated on February 2018

Everolimus Modulation of Anti-tumor T CD4 Immune Responses


Brief description of study

Everolimus is an inhibitor of mammalian target of rapamycin, approved in patients with metastatic renal cell carcinoma.

The objective of this study is to investigated the influence of everolimus immune modulation on antitumor efficacy .

Clinical Study Identifier: NCT02837757

Find a site near you

Start Over